Nieuws
TipRanks on MSN1d
Sarepta price target raised to $12 from $6 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Sarepta (SRPT) to $12 from $6 and keeps a Sell rating on the shares. After ...
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
Stocktwits on MSN1d
This Analyst Says Sarepta Lost Credibility By Exiting Arrowhead At A Loss, But Retail Sees Stock Hitting $30 By Next Week
H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...
Investing.com -- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) stock dropped 6% after Sarepta Therapeutics (NASDAQ:SRPT) announced it sold over 9.2 million shares of Arrowhead in a privately negotiated ...
Sarepta Therapeutics sells 9.3M Arrowhead shares for $174M and fulfills a $100M milestone payment. Read more here.
Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.
De FDA concludeerde dat het overlijden van een 8-jarige patiënt niet gerelateerd was aan Elevidys, waardoor leveringen aan ambulante DMD-patiënten konden worden hervat. Elke levering zal nu vergezeld ...
De opwaardering volgt op de hervatting van de ELEVIDYS-levering voor ambulante patiënten, wat volgens Freedom Broker-analist Ilya Zubkov de vooruitzichten voor Sarepta’s inkomstentraject op ...
Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...
Sommige resultaten zijn verborgen omdat ze mogelijk niet toegankelijk zijn voor u.
Niet-toegankelijke resultaten weergeven
Feedback